Long- vs Short-Course Radiation Therapy in Rectal Cancer
This video reviews some of the pros and cons of long-course and short-course radiation therapy for the neoadjuvant treatment of rectal cancer.
In this video, Chi Lin, MD, PhD, of the University of Nebraska Medical Center, discusses some of the pros and cons of long-course and short-course radiation therapy for the neoadjuvant treatment of rectal cancer.
Lin gave a presentation on this topic during an education session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
